Sutro Biopharma is a clinical-stage company developing next-generation antibody-drug conjugates (ADCs) for cancer. Its proprietary cell-free protein synthesis platform enables precise, site-specific design of antibodies, linkers and payloads—including multi-payload constructs—with the aim of improving stability, exposure and therapeutic index. Programs target solid tumors and other oncology indications where conventional ADCs leave room for optimization.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 17.4 | — | -76 | — |
| Q2 2025 | 63.7 | — | -11.5 | — |
| Q3 2025 | 9.7 | — | -56.9 | — |
| Q4 2025 | 11.7 | — | -46.8 | — |
| Q1 2026 | 14.5 | -16.5% | -38.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Blue Water Acquisition Corp. III (BLUW), Abeona Therapeutics Inc. (ABEO), PrimeEnergy Resources Corporation (PNRG), Agencia Comercial Spirits Ltd (AGCC), CPI Card Group Inc. (PMTS), FS Bancorp, Inc. (FSBW)